| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in millions, except per share data) | Quarter Ended December 31, 2025 | | Full-Year Ended December 31, 2025 |
| Acquired IPR&D and Milestones Expense | | Adjusted Diluted EPS Range | | Acquired IPR&D and Milestones Expense | | Adjusted Diluted EPS Range |
| | Low | | High | | | Low | | High |
| Previously announced guidance excluding Q4 2025 acquired IPR&D and milestones expense | $ | — | | | $ | 3.32 | | | $ | 3.36 | | | $ | 3,751 | | | $ | 10.61 | | | $ | 10.65 | |
| Q4 2025 acquired IPR&D and milestones expense | 1,265 | | | (0.71) | | | (0.71) | | | 1,265 | | | (0.71) | | | (0.71) | |
| Guidance including Q4 2025 Acquired IPR&D and milestones expense | $ | 1,265 | | | $ | 2.61 | | | $ | 2.65 | | | $ | 5,016 | | | $ | 9.90 | | | $ | 9.94 | |